Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced bre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Bella, Stein, Steven, Casey, Michelle A, Newstat, Beth O
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727787/
https://www.ncbi.nlm.nih.gov/pubmed/19707428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727787/
https://www.ncbi.nlm.nih.gov/pubmed/19707428

Ejemplares similares